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To the Editor 37 
 Bronchiolitis is the leading cause of infant hospitalizations in the US (1). Two distinct 38 
viruses – respiratory syncytial virus (RSV) and rhinovirus (RV) – account for most cases of severe 39 
bronchiolitis (i.e, bronchiolitis requiring hospitalization) (1). Although bronchiolitis is traditionally 40 
discussed as a single entity and currently-available treatment does not vary by viral etiology (2), 41 
emerging evidence suggests heterogeneity in the pathobiology of bronchiolitis by infecting virus. 42 
For instance, epidemiological investigations have shown that children with RSV bronchiolitis have 43 
different demographics, higher acute severity, and lower risk of developing childhood asthma 44 
compared to RV bronchiolitis (3,4). Studies have further demonstrated multiple clinical phenotypes 45 
of bronchiolitis (5), with between-virus (RSV vs. RV) differences in upper airway metabolomic 46 
profiles and bacterial colonization (6). However, it remains unclear whether the host systemic (i.e., 47 
serum) response differs by infecting virus. To address this knowledge gap, we examined the 48 
difference between RSV and RV infections using metabolomic profiling (i.e., comprehensive 49 
characterization of small-molecule metabolites that represent the functional activity of the host) to 50 
serum samples of infants with severe bronchiolitis. 51 
 52 
We analyzed data from the 35th Multicenter Airway Research Collaboration (MARC-35), 53 
an ongoing, multicenter, prospective cohort study of infants with severe bronchiolitis (7). The study 54 
design, setting, participants, and methods of data collection have been reported previously (8). 55 
Briefly, MARC-35 enrolled infants (age <12 months) hospitalized with attending physician 56 
diagnosis of bronchiolitis at 17 sites across 14 US states during 2011-2014 winter seasons. 57 
Bronchiolitis was defined by the American Academy of Pediatrics guidelines – acute respiratory 58 
illness with some combination of rhinitis, cough, tachypnea, wheezing, crackles, and retractions (2). 59 
We excluded infants with previous enrolment, those who were transferred to a participating hospital 60 
>24 hours after the original hospitalization, those who were consented >24 hours after 61 
hospitalization, or those with known heart-lung disease, immunodeficiency, immunosuppression, or 62 
gestational age <32 weeks. The institutional review board at each of the participating hospitals 63 
approved the study. Written informed consent was obtained from the parent or guardian.  64 
Metabolomic profiling of serum samples collected within 24 hours of hospitalization was 65 
performed with ultra-high performance liquid chromatography-tandem mass spectrometry, as 66 
detailed previously (9). To examine the between-virus difference in the overall metabolomic 67 
profile, orthogonal partial least squares-discriminatory analysis (OPLS-DA) with 2000 68 
permutations was performed. To determine individual discriminatory metabolites, linear random-69 
effects models adjusting for age, sex, race/ethnicity, prematurity, history of systemic corticosteroid 70 
use, and potential patient clustering at hospital-level were constructed, with the use of Benjamini-71 
Hochberg false discovery rate (FDR). We did not adjust for acute severity markers (e.g., 72 
mechanical ventilation use) as these were considered intermediates in the association of interest. 73 
The analysis was performed using R version 3.5 (10) and MetaboAnalyst 3.0 (11). 74 
 75 
The current investigation analyzed 116 infants with bronchiolitis who had, by design, over-76 
representation of rhinovirus infection – 79 with RSV-only (68%) and 37 with RV-only (32%). 77 
Overall, the median age was 3.0 months (IQR 1.2-5.7 months), 62% were male, and 38% were non-78 
Hispanic white. Most patient characteristic did not differ (P>0.20), including sex, race, maternal 79 
smoking status, smoke exposure, eczema, gestational age, receipt of breast milk, and antibiotic use. 80 
Infants with RSV-only bronchiolitis were younger than those with RV-only (P=0.002).  81 
Serum metabolomic testing identified a total of 708 metabolites from 91 sub-pathways 82 
within 8 super-pathways. In OPLS-DA, the overall metabolomic profile of infants with RSV-only 83 
and that of RV-only clustered distinctly (Ppermutation=0.006; Figure 1A). Of the 708 identified 84 
metabolites, 151 metabolites had significantly different intensities between groups after adjusting 85 
for potential confounders and patient clustering: 21 metabolites were higher in the RSV-only group, 86 
while 130 metabolites were higher in the RV-only group (FDR<0.05).  87 
Lipids accounted for 76% (16/21) of metabolites that were significantly enriched in RSV-88 
only, but 35% (45/130) of metabolites significantly enriched in RV-only (P<0.001). In the RSV-89 
only group, palmitoleate (16:1n7) (long-chain fatty acid sub-pathway) was the most significantly 90 
enriched lipid. In the RV-only group, 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) 91 
(phosphatidylinositol sub-pathway) was the most significantly enriched lipid. By contrast, amino 92 
acid metabolites accounted for only 10% (2/21) of metabolites significantly enriched in RSV-only, 93 
while they accounted for 34% (44/130) of metabolites enriched in RV-only (P=0.04). For example, 94 
within the amino acid super-pathway, the RV-only group had significantly enriched N-acetyl 95 
metabolites – N-acetylarginine, N-acetylglutamate, N-acetyltaurine , N-acetylvaline. and N-96 
acetylleucine (all FDR<0.05). Similar to the OPLS-DA, the unsupervised clustering of 20 most 97 
significant metabolites separated infants with RSV-only bronchiolitis from those with RV-only 98 
bronchiolitis. (Figure 1B). These differences between the qualitative virus status were also 99 
supported by the correlations between the quantitative viral differences (i.e., virus genomic load 100 
based on inverse cycle threshold values) and significant metabolites (Figure 2). 101 
 102 
These observations lend additional support to the emerging concept that there is 103 
heterogeneity in bronchiolitis pathogenesis (3–7), at least, by two major respiratory viruses (RSV 104 
and RV). We found that the overall serum metabolomic profiles and a large proportion of individual 105 
metabolites differed significantly between the viral groups. Consistent with the current study, we 106 
previously demonstrated relationships between respiratory viruses, different metabolic pathways in 107 
the nasopharyngeal airway, and disease severity in infants with severe bronchiolitis (6,8). These 108 
investigations of airway metabolomics demonstrated not only the associations of lipid metabolites 109 
with higher disease severity, but also the associations of RV infection with N-acetyl amino acid 110 
metabolites. While serum data most likely reflects the host responding to environmental stimuli 111 
systemically, whether local and/or circulating metabolites can alter virus infectivity merits further 112 
investigation. Our data corroborate earlier studies that showed the between-virus differences in host 113 
local response and molecular mediators in nasopharyngeal aspirates (12,13), and extend them by 114 
demonstrating the virus-specific metabolomic signatures reflecting the differences in host systemic 115 
response.  116 
different metabolomic profiles are an important determinant of the susceptibility of infection 117 
and/or different respiratory virus.  Alternatively, a metabolomic profile could simply be a marker of 118 
an infant who is prone to specific virus infection. Additionally, reverse causation – i.e., infection to 119 
a specific virus and subsequent host response perturbate metabolic states – is also possible. This 120 
study has potential limitations. First, the analytic cohort was relatively small and these novel 121 
findings will need to be validated in independent datasets. Second, the cross-sectional nature of the 122 
study design precludes temporal analysis and additional experimentation in model systems will be 123 
necessary to determine cause or effect. Third, we examined the relationships of respiratory virus 124 
with serum metabolome data while bronchiolitis involves a complex interplay among viral, 125 
microbiome, and host. Additional datasets (e.g., metagenomics, host genomics, transcriptomics) 126 
would gain a more holistic understanding of disease mechanism. Lastly, although our study sample 127 
was racially/ethnically- and geographically-diverse, all were hospitalized for bronchiolitis. 128 
Therefore, inferences should be made cautiously to children with mild-to- moderate bronchiolitis. 129 
Regardless, our findings remain directly relevant to 130,000 hospitalized American children each 130 
year (1).  131 
In summary, the current multicenter analysis demonstrated, for the first time, that the virus 132 
infecting the airways of infants with severe bronchiolitis is significantly associated with different 133 
serum metabolomic signatures.  In conjunction with prior studies, our findings suggest that the 134 
pathobiology of bronchiolitis differs between RSV and RV infection, which has direct implications 135 
for the development of targeted treatment strategies.  Our data should advance research into the 136 
complex interplay between respiratory viruses and host response and their contributions to 137 
bronchiolitis morbidities.    138 
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FIGURE LEGENDS 175 
 176 
Figure 1. Association of respiratory syncytial virus (RSV)-only and rhinovirus (RV)-only 177 
bronchiolitis with serum metabolomic profile.  178 
Data based on serum metabolites among infants with RSV-only (n=79) compared to those with RV-179 
only (n=37) infection.  180 
(A) Orthogonal partial least squares–discriminatory analysis (OPLS-DA) score scatter plot. Each 181 
dot is the representation of the serum metabolomic profile of a single infant in a two-dimensional 182 
space. The ellipses represent the 95% confidence interval. The overall serum metabolomic profiles 183 
of infants with RSV-only and that of RV-only clustered distinctly (P=0.006 with 2000 random 184 
permutations). 185 
(B) Unsupervised hierarchical clustering of the 20 most significant metabolites using Euclidean 186 
distance with Ward linkage. Infants are shown in columns. Metabolites are shown in rows with the 187 
color representing the log-transformed intensity of metabolites, where blue is low and red is high. 188 
The row dendrogram is colored according to the metabolite being increased in RSV-only (red) or 189 
RV-only (green) and metabolite names are colored according to their super-pathway.  190 
 191 
 192 
 193 
Figure 2. Correlations of the viral genomic load (measured as the inverse cycle threshold 194 
value) with 20 most significant metabolites.  195 
Data based on serum metabolomics among infants with respiratory syncytial virus (RSV)-only 196 
(n=79) compared to those with rhinovirus (RV)-only (n=37) bronchiolitis.  Only the 20 most 197 
significant metabolites are shown.  Canonical correlations are based on sparse partial least squares 198 
(sPLS) analysis of the metabolite intensity with the inverse viral genomic load. The row 199 
dendrogram is colored according to the metabolite being increased in RSV-only (red) or RV-only 200 
(green); the metabolite names are colored according to their super-pathway.  201 
 202 
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